Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by James Learned
In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.
Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 14 September 2010 12:49
- Written by Liz Highleyman
Chronic hepatitis B treatment using entecavir (Baraclude) for 1 year is good, but 3 years is better, according to an international study published in the September 2010 issue of Hepatology. Patients who received at least 3 years of cumulative entecavir therapy showed substantial histological improvement on liver biopsies and experienced regression of liver fibrosis or cirrhosis.
Appetite-regulating Hormone Ghrelin May Inhibit Inflammation and Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 23 March 2010 14:02
- Written by Liz Highleyman
Ghrelin, an appetite-regulating hormone produced primarily in the stomach, reduced liver fibrosis, inflammation, and oxidative stress in rats and protected them from both chronic and acute liver injury, according to a study published in the March 2010 issue of Hepatology. Researchers also found that ghrelin levels were lower in chronic hepatitis patients with advanced fibrosis. If confirmed in future studies, ghrelin may have potential as an anti-fibrotic therapy.
Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 08 June 2010 12:49
- Written by Liz Highleyman
Interaction between hepatitis B virus (HBV) and the androgen receptor in the liver promotes viral replication and triggers cell changes that lead to development of hepatocellular carcinoma, according to a study in mice described in the May 19, 2010 issue of Science Translational Medicine. Since men have more active androgen receptors than women, these findings help explain why men with hepatitis B are more prone to liver cancer, and suggest that blocking androgen receptors in the liver might be an effective treatment.
Bone Loss and Vitamin D Deficiency Are Common among People with Liver Cirrhosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 01 September 2009 14:01
- Written by Liz Highleyman
People with liver cirrhosis -- a potential outcome of chronic hepatitis B or C -- frequently experience bone loss, or reduced bone mineral density (BMD), and often have low vitamin D levels, according to an Indian study published in the July 28, 2009 issue of World Journal of Gastroenterology.
Web Design and Development by